top of page

Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December

President and CEO Robert Blum describes aficamten's mechanism, the trial's study design, and reflects on Cytokinetics' journey of 25 years in drug development.


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page